Can't Get There from Here?
Adjuvant Induces T Cells, but Keeps Them for Itself
By Anette Breindl
Friday, March 8, 2013
Cancer immunotherapy has high hopes riding on it these days. In contrast to the spectacular but extremely short-lived effects of targeted therapies, where immunotherapy works, it often leads to remissions that last for years. But it doesn't work often.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.